Community post
Avatar
Iliana • Admin
Multiple Myeloma Discussion • September 30, 2024
New Trial Opportunity for Relapsed Myeloma
AI-generated title
A phase III study by Bristol Myers Squibb is open comparing a new oral drug called mezigdomide (CC-92480), bortezomib and dexamethasone vs. pomalidomide, bortezomib and dexamethasone. Mezigdomide is part of a new class of drugs called CELMoDs. Study participants who have relapsed or refractory myeloma, prior exposure to lenalidomide and at least 1-3 lines of therapy are welcome to join. Learn more about this study here: https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT05519085?cid=s_2839272
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | BMS Clinical Trials

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | BMS Clinical Trials

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT05519085?cid=s_2839272
Avatar

No comments yet.

Related Content